Aadi Bioscience (FRA:3350) Gross-Profit-to-Asset % : 15.47% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Aadi Bioscience's annualized Gross Profit for the quarter that ended in Mar. 2024 was €17.30 Mil. Aadi Bioscience's average Total Assets over the quarter that ended in Mar. 2024 was €111.81 Mil. Therefore, Aadi Bioscience's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 15.47%.

Aadi Bioscience Gross-Profit-to-Asset % Historical Data

The historical data trend for Aadi Bioscience's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Gross-Profit-to-Asset % Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

74.37

1.14

8.36

13.38

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial										11.97	13.70	14.58	15.70	15.47

Competitive Comparison of Aadi Bioscience's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Aadi Bioscience's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aadi Bioscience's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's Gross-Profit-to-Asset % falls into.

Aadi Bioscience Gross-Profit-to-Asset % Calculation

Aadi Bioscience's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	19.757	/	( (173.92	+	121.432)	/ 2 )
	=	19.757	/	147.676
	=	13.38 %

Aadi Bioscience's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	17.3	/	( (121.432	+	102.187)	/ 2 )
	=	17.3	/	111.8095
	=	15.47 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Aadi Bioscience Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience (FRA:3350) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

AADI:USA 3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines